CrossrefInfokarte
Efficacy and safety of once-weekly somatrogon following up to 4 years of treatment in Japanese children with growth hormone deficiency: results from an open-label extension of a phase 3 study
Endocrine Journal · 2026 · 73 (1) · 21-32
DOI: 10.1507/endocrj.ej24-0625 ↗Abstract
Kein Abstract verfügbar.
EUVIMED